Fig. 2From: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217Differences in plasma p-tau217 according to amyloid status. CSF-Aβ+ was determined by CSF Aβ42/Aβ40 ratio < 0.07, and amyloid-PET+ was determined by >1.42 SUVR. AUC, area under the curveBack to article page